AWM338 | Profit.ly

Toy Streaming?

I was a bit late starting my preparation today due to the time I took going through some house buying paperwork - why is it that solicitors need to say things in such obscure ways?

BBIG - Toys and Packaging

Bethlehem, PA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Vinco Ventures, Inc. (NASDAQ: BBIG) and ZASH Global Media and Entertainment Corporation (“ZASH”), a U.S. based entertainment, content and distribution company, today announced the signing of an Agreement to Complete a Plan of Merger subject to certain conditions, creating exciting acceleration and growth in live-streaming content, video-sharing, distribution and production within its own ecosystem.

GENE

MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.

Key Highlights

Total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients’ data

º Predictive capabilities improved 100% over age and sex alone ¹

º Analysis confirms that the test is well calibrated ²

º Further datasets will continue to enhance the accuracy and consistency of the algorithm
Anticipate submission for regulatory clearance via Centers for Medicare and Medicaid Services/Clinical Laboratory Improvement Amendments (CMS/CLIA) by the end of Q1 CY21 following final validation process of expanded dataset
In active conversations on commercialization opportunities in conjunction with CLIA regulatory submission and clearance
Additionally, as previously announced, the Company has commenced with equipment calibration along with specialized inhouse training of the scientific team to establish the Germline Testing division for hereditary cancer risk with initial focus on:

º BRCA testing to be offered in conjunction with GeneType for Breast Cancer, and

º Lynch Syndrome testing to be offered in conjunction with GeneType for Colorectal Cancer

A good daily chart since June 2020

CLSN

On January 20, 2021, the Company delivered notice to Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“Lincoln Park Capital”) terminating the Purchase Agreement, dated September 8, 2020 (the “2020 Purchase Agreement”), with Lincoln Park Capital effective January 21, 2021 (the “Termination Date”). The 2020 Purchase Agreement provided that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park Capital up to $26 million of shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), over the 36-month term of the 2020 Purchase Agreement. In consideration for entering into the 2020 Purchase Agreement, the Company issued to Lincoln Park Capital 437,828 shares of the Company’s Common Stock.

Concurrently with entering into the 2020 Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park Capital (the “Registration Rights Agreement”), pursuant to which the Company agreed to file one or more registration statements, as permissible and necessary under the Securities Act of 1933, as amended (the “Securities Act”), to register the sale of the shares of the Company’s Common Stock that have been and may be issued to Lincoln Park Capital under the 2020 Purchase Agreement. On September 8, 2020, the Company filed a Prospectus Supplement to the Prospectus dated October 12, 2018 with the Securities and Exchange Commission registering all the shares of Common Stock that may be offered to Lincoln Park Capital from time to time under the 2020 Purchase Agreement. From September 8, 2020 through the Termination Date, the Company sold 2,845,000 shares of Common Stock under the 2020 Purchase Agreement generating proceeds of $2.2 million. The Company has no further obligations under the 2020 Purchase Agreement.

The descriptions of the 2020 Purchase Agreement and the Registration Rights Agreement contained in this Current Report on Form 8-K do not purport to be complete and are qualified in their entirety by reference to the copies of the 2020 Purchase Agreement and the Registration Rights Agreement filed as Exhibit 10.1 and Exhibit 4.1, respectively, to the Current Report on Form 8-K filed on September 8, 2020.